Celldex Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Celldex Therapeutics, Inc. (CLDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 1.20% for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2021-11-09
- Celldex Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-09-30 was 1.20%.
- Celldex Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-06-30 was 1.30%.
- Celldex Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 1.20%.
- Celldex Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-09-30 was 1.90%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month |
|---|---|---|---|
| 2021-09-30 | 1.20% 10-Q · filed 2021-11-09 | 1.30% 10-Q · filed 2021-11-09 | |
| 2021-06-30 | 1.30% 10-Q · filed 2021-08-05 | 1.30% 10-Q · filed 2021-08-05 | |
| 2021-03-31 | 1.20% 10-Q · filed 2021-05-06 | ||
| 2020-09-30 | 0.60% 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | 0.60% 10-Q · filed 2021-08-05 | ||
| 2019-09-30 | 1.90% 10-Q · filed 2020-11-05 | 2.50% 10-Q · filed 2020-11-05 | |
| 2019-06-30 | 2.40% 10-Q · filed 2020-08-06 | 2.50% 10-Q · filed 2020-08-06 | |
| 2018-09-30 | 3.00% 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | 3.00% 10-Q · filed 2019-08-07 | ||
| 2017-09-30 | 2.30% 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | 2.10% 10-Q · filed 2018-08-08 | 2.30% 10-Q · filed 2018-08-08 | |
| 2016-06-30 | 1.60% 10-Q · filed 2016-08-08 | ||
| 2015-06-30 | 2.20% 10-Q · filed 2016-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |